The article reports on the treatment of early breast cancer through adjuvant therapy with aromatase inhibitors. Experiment results showed improved event-free survival and a trend for improved survival in women who switched to aromatase inhibitor therapy. The clinical trial run by the National Cancer Institute of Canada suggests the proper dosage for the inhibitor.